Cover
Vol. 2 No. 2 (2012)

Published: December 31, 2012

Pages: 22-24

Research Article

Evaluation of PSA tumor marker in some Iraqi women with polycystic ovarian syndrome

Abstract

Background: Polycystic ovarian syndrome (PCOS) is the most common cause of hyperandrogenism anovulatory infertility; it affects 5-10% female reproductive age. The present study aims to investigate the total prostate specific antigen levels, total serum testosterone, FSH and LH in women with PCOS and compare the results with control group of normal fertile females of corresponding age group on Iraqis PCOS patients. Materials and Methods: Seventy patients with PCOS diagnosed depending on three criteria: Menstrual history: Oligomenorrhea, Ultrasound reveals polycystic ovaries and Biomedical and/ or clinical hyperandrogenism. Twenty normal fertile females who serve as control group in this study. Blood samples were aspirated from all individuals from 2-4 day of menstrual cycle to measure total prostate specific antigen(PSA), total testosterone and FSH, LH. Results: Patients with PCOS and controls differed significantly in PSA, Total serum testosterone (p<0.05). Patients with PCOS and controls have highly significant difference in LH level, the mean was (7.88±1.83 vs 3.90±0.73) respectively highly significant difference in LH/FSH ratio and BMI parameters (p<0.001). No significant differences were found in FSH (p>0.05). Positive correlation between PSA and testosterone, PSA and BMI. Conclusion: Total serum prostate specific antigen levels are higher in patient with PCOS. Total testosterone levels are higher in patient with PCOS. Serum PSA measurement might be marker of hyperandrogenism in females suffering from PCOS.

References

  1. Norman RJ Dewailly D. Legro RS, et al Polycystic cvary syndrome. Lancet 2007; 370:685-697.
  2. Revised 2003 consensus diagnostic criteria ard long-term heath risks related ovary syndrome Hum Reprod
  3. 'edel E. Waern M. Gustafson D. et a'. Anxiety and depression symptcnls in women with polycystic ovary syndrome compared with conns matched for body mass index. Hum Revco
  4. Li Y, Yu Ng EH E. et Polycystic associated wth regatvety variable ingas on domains of health-related quality of Me: evidence from anela anabsis_ Fefil Sei' 2011
  5. Consensus Revised 21203 consensus c.' diagnostic criteria and Ong-term reailh risks related 10 polycystic ova.'ysyndr&me_ Feril Steril 200481: 19-25
  6. Ablin, R', Soanes WA, Bronson P, etal Precipitating antoens Of the nonl human J Reprod Fertil, 1970.22:573
  7. Hara. M. k0FnÉ, Y. Inoue.T. ef d. Sane characteistics ot nwserincprotein. an antigenic component specific for human seminal plan. 1971 25322
  8. 8,Chan. Bruek, Ceslfflhy et Pros* Talker pros%te car-ær: 1987.33:191ö.
  9. LD. Warg ','C, VåEnzueLaLA, ofprcgtes caru patent 1330
  10. IJKerre'h WK Wal. Paul -Jare lee Human PSA structJral furdorå simlanty Lith Nalzral 3156-3171
  11. 4, Purifutjcns a
  12. LC, Kunpra M et a'. Ptcæ mbprr, area Vial makg for prcstakcanær_ Prostate lg81 2;8g.g6
  13. H, J RarrE'ik G e,' a' Seriral veS:k -;t01E-irs arc geldionard Iti.eZbncthuTanseren, J Clin Ines11987 281 •285
  14. A Kdlik•eil - Ae serine protease céaves g,8d0TirgntETiral Clin
  15. 199724275-282,
  16. lö N. C,'ass, L, art Dinands EP. Stecid hcrrr,crerquetjcn of PSA in breast carcer B' J Carær. 1997 75; 579-58
  17. Xia N Tsatscubs A. Fertile gwa-mmhg 01 PCOS b'/ exrss, Cline Clin
  18. Yliiz 3 C. "our S, K. e' al. ecring Kum. REprod update. 201016, 51-4
  19. A, Brena K and Aziz R of hyp:ranlrcgenemia i' he polycysti: cva-y by the Nalini Institutes of Health 1990 cite-a. Fell, SW 201093, 1938-1941.
  20. Neson VL. Ch Ku, Rc€erfeli RI, e,' Tre bizchemu Estcstgore;rcdJcbcn in treca *Its kith *ycrsbc syrfire, Cin
  21. Gtsh D. Gisb0t J, Em-an gt basis tr anhge *Afcity ard cesti*' syntress In numanaro•nüse VÜre 219457 nay: 219-23
  22. M. Stozu Ogata Vde:dz bæes arc *errrinanS d arcmataseexces Iru Endo:ind. 2012.5E7.
  23. Yu H, tiarnard,s F, et P,astaÉsgecifcnlige1 in carær. bentn lisse aeastCanær Res Teal 19%, •j 171-178
  24. Rifat E. S A n h&lte Turish' E.nd:crintilnvesl 26 202.
  25. S J IF, Hdl E et at the h',VhdaTic- gituilay axe wore-. pclyc'fbc 'Wim disease 'direct partial gm.%ctoph deerstizäi:n, Cin 5&tö5• 172
  26. z DJ. lncn W. JakJtcWra S. et a'. Efects ct redtrrril on arry 87:524-529
  27. Kaksaros Meb;os arc Diarrards PSA production by' turnrs ater oral antraceptve, Cin Eicd•en 199, 31; 28528b,
  28. &uCV.ScmlasA. a'. Prcsäte smficanbgen ndturanglnduur •kren 2 a-e rrarediy ee,ated i unre W.' pdyv,sbc oa•y synfire Cin
  29. Ansa-T A] dame. Snrner H and Awatf J. Can PSA te a prcriSng market for *ers wth PCOS ari hrsutsm? East JcuTä 2{04; g: 3
  30. M, Tzcal A, geytlli G, Seum keels spe;ifc 2ntge•l and amir—s rayl a agcnist n 'horren. Gyrecd Endtcind. 2035; 57: 20